2X1:ETR
Abivax SA
76,90 €
arrow_downward
-1,47%(-1,15) 1D
6. nov., 17.35.32 GMT+1 · EUR
search
Alle symboler
| Symbol | Pris | Ændring | Ændring i % |
|---|
insights_autoGenererer vigtig indsigt for 2X1...
Åbn
74,30 €
Høj
76,90 €
Lav
74,30 €
Markedsværdi
6,84 mia.
Gns. vol.
975,00
Volumen
507,00
Højeste i 52 uger
137,40 €
Laveste i 52 uger
60,85 €
Indtægt pr. aktie
-5,20 €
Antal ansatte
98
Åbn
74,30 €
Høj
76,90 €
Lav
74,30 €
Markedsværdi
6,84 mia.
Gns. vol.
975,00
Volumen
507,00
Højeste i 52 uger
137,40 €
Laveste i 52 uger
60,85 €
Indtægt pr. aktie
-5,20 €
Antal ansatte
98
Nyhedshistorier
Fra webkilder og nyhedspartnere
Traders Union
·
for 15 timer siden
Teknisk analyse af S&P 500: Oversolgt CCI og Stoch RSI peger på mulighed for rebound
Invezz
·
for 16 timer siden
Nasdaq stiger 1% efter chip-opsving; Dow falder trods stærke jobtal
Trefis
·
for 1 time siden
S&P 500 Movers | Winners: COHR, ABNB, AMD | Losers: AXON, MCHP, CHTR
The Daily News | Texas' Oldest Newspaper
·
for 1 time siden
Nasdaq rebounds but posts fourth straight weekly decline
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Om Abivax SA
Administrerende direktørMarc de Garidel | Hartmut J. Ehrlich
Ansatte98
Grundlagt4. dec. 2013
Hovedsæde-
SektorHealth Care
Branche-
Websiteabivax.com